Survival analysis of phase 2 patients. (A) OS of all 22 patients in phase 2 at 24 months is estimated to be 41% ± 13%. (B) Comparison of survival of patients who completed reinduction. Survival was significantly better in those who responded (CR or CRp) compared with those who did not (P < .001).